Anti-infective
Pfizer, which licensed the candidate from Valneva, said the vaccine demonstrated clinically meaningful efficacy for preventing Lyme disease, even though the study failed to accrue enough cases.
Since being taken private by B-FLEXION, Paratek has been building out its commercial portfolio and Radius’s osteoporosis drug Tymlos will advance that strategy.
Moderna will pay $950m upfront under the settlement, which lifts a significant weight off its shoulders, as investors had feared it could be on the hook for $5bn.
Albert Bourla has once again been outspoken in his criticism of Vinay Prasad’s attempts to overrule FDA staff approval recommendations for vaccines, but he was more positive about other US policy reforms.
The Japanese industrial material group expands its global presence with a strategic niche focus on immunology, organ transplantation, and severe infectious diseases.
Asahi Kasei’s €780m acquisition of AiCuris strengthens its anti‑infectives portfolio through immediate Prevymis royalties and the near‑term commercial potential of pritelivir.
The drugmaker presented Phase III data at CROI showing the two-drug combination pill is non-inferior to existing options like Gilead’s Biktarvy, both in treated and untreated HIV patients.
Gilead anticipates that the single-pill combination’s novelty will make it an attractive new option for patients already virologically suppressed.
With Phase IIb initiation planned in the second quarter, Altesa is advancing an antiviral candidate in COPD that aims to address viral triggers rather than underlying inflammation alone.
The company announced updated data showing superiority for the long-acting injectable over daily pills among patients with adherence challenges.
Phase II results have boosted hopes for alpibectir, which the partners believe could transform pulmonary tuberculosis and meningitis tuberculosis treatment, and earn up to $400m a year.
The company said the FDA has now accepted its application for mRNA-1010, but it will have to do a postmarketing study in individuals aged 65 and older.
The company expressed disappointment at the FDA’s decision to reject the mRNA flu vaccine’s submission, during its fourth-quarter earnings call on Feb. 13.
Enthusiastic predictions from industry leaders for ongoing progress in obesity, oncology, immunology, neuroscience and more were supported by optimism for the potential of AI and other technological advances to enable breakthroughs in processes as well as pipelines.
While a record number of China-originated first-in-class drugs were approved domestically in 2025, only one has so far entered clinical development overseas with its originator as the sole sponsor. But more progress is expected this year.
Valneva's withdrawal of its chikungunya vaccine leaves Bavarian Nordic as the only remaining firm producing a shot for the condition in the US.
Novavax will get $30m up front for a non-exclusive license for its Matrix-M adjuvant, but the deal could bring in billions long-term. The biotech is negotiating similar deals with multiple firms.
The US giant is narrowing its focus on obesity and cancer.
Bepirovirsen, which GSK licensed from Ionis in 2019, is one of the 15 pipeline products that the British drugmaker has said could cross over £2bn in peak annual sales.
A year after Valneva entered a tech transfer agreement for its chikungunya vaccine with Serum Institute, the deal has been called off. Regulatory approvals for the vaccine in Asia are yet to be obtained and the biologics license for Ixchiq remains suspended in the US. What happens hereon?